395 related articles for article (PubMed ID: 28780375)
41. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
[TBL] [Abstract][Full Text] [Related]
42. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
Lim PY; Hickey AC; Jamiluddin MF; Hamid S; Kramer J; Santos R; Bossart KN; Cardosa MJ
Vaccine; 2015 Nov; 33(44):6017-24. PubMed ID: 26271825
[TBL] [Abstract][Full Text] [Related]
43. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
44. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale.
Rosenthal JA; Chen L; Baker JL; Putnam D; DeLisa MP
Curr Opin Biotechnol; 2014 Aug; 28():51-8. PubMed ID: 24832075
[TBL] [Abstract][Full Text] [Related]
45. Platforms, advances, and technical challenges in virus-like particles-based vaccines.
Gupta R; Arora K; Roy SS; Joseph A; Rastogi R; Arora NM; Kundu PK
Front Immunol; 2023; 14():1123805. PubMed ID: 36845125
[TBL] [Abstract][Full Text] [Related]
46. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
Garg H; Sedano M; Plata G; Punke EB; Joshi A
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
[TBL] [Abstract][Full Text] [Related]
47. Toward precision adjuvants: optimizing science and safety.
Nanishi E; Dowling DJ; Levy O
Curr Opin Pediatr; 2020 Feb; 32(1):125-138. PubMed ID: 31904601
[TBL] [Abstract][Full Text] [Related]
48. Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.
Vasou A; Sultanoglu N; Goodbourn S; Randall RE; Kostrikis LG
Viruses; 2017 Jul; 9(7):. PubMed ID: 28703784
[TBL] [Abstract][Full Text] [Related]
49. Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.
O'Rourke JP; Peabody DS; Chackerian B
Curr Opin Virol; 2015 Apr; 11():76-82. PubMed ID: 25829254
[TBL] [Abstract][Full Text] [Related]
50. Novel adjuvants & delivery vehicles for vaccines development: a road ahead.
Mohan T; Verma P; Rao DN
Indian J Med Res; 2013 Nov; 138(5):779-95. PubMed ID: 24434331
[TBL] [Abstract][Full Text] [Related]
51. Immunologic adjuvants for modern vaccine formulations.
Vogel FR
Ann N Y Acad Sci; 1995 May; 754():153-60. PubMed ID: 7625649
[TBL] [Abstract][Full Text] [Related]
52. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
[TBL] [Abstract][Full Text] [Related]
53. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
54. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
55. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
56. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
[TBL] [Abstract][Full Text] [Related]
57. Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset F; Vazquez T; Bellier B
Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
[TBL] [Abstract][Full Text] [Related]
58. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
[TBL] [Abstract][Full Text] [Related]
59. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.
Kushnir N; Streatfield SJ; Yusibov V
Vaccine; 2012 Dec; 31(1):58-83. PubMed ID: 23142589
[TBL] [Abstract][Full Text] [Related]
60. The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.
Meshram CD; Baviskar PS; Ognibene CM; Oomens AGP
J Virol; 2016 Dec; 90(23):10612-10628. PubMed ID: 27654298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
